bluuebunny/crossref_metadata_2025 huggingface dataset:
Efecto del Ejercicio Físico en la Asociación entre las Horas de Sueño y el Infarto de Miocardio
Authors: Miranda Patricio A. , Murillo Ana C.
Published: November 2024

Introducción: El dormir menos se asocia con el desarrollo de infarto de miocardio (IM). Aunque existe investigación sobre la asociación entre horas de sueño e IM, aún se desconoce si la actividad física tendrá un efecto sobre la asociación entre estas variables. Objetivos: Valorar el efecto de la actividad física en la asociación entre horas de sueño e infarto de miocardio en adultos de EE. UU del 2018. Métodos: Estudio transversal, usando datos del BRFSS 2018 (N=437,436). Se incluyeron estadounidenses ≥18 años. La variable independiente fue horas de sueño y la variable dependiente IM. El modificador del efecto fue actividad física. Las covariables fueron edad, sexo, raza, fumar tabaco, índice de masa corporal y salud mental. Se aplicó un modelo de regresión logística ajustado y no ajustado, calculando los odds ratio (OR) e intervalos de confianza (IC) 95%. Resultados: El análisis se estratificó según actividad física. Comparado con un valor de referencia de duración del sueño de 7-8h, los OR (IC 95%) en individuos que si realizan ejercicio fueron 1.62 (1.52-1.72), 1.07 (1.02-1.13) y 1.46 (1.37-1.56) para duraciones de sueño de ≤5h, 6h y ≥9h. Mientras que, si no la realizan fueron 1.62 (1.51-1.74), 1.17 (1.10-1.25) y 1.27 (1.18-1.37) para duraciones de sueño de ≤5h, 6h y ≥9h. Conclusiones: La actividad física tiene efecto modificador en duraciones de sueño de 6h y ≥9h. Los resultados dan apertura a estudios que muestren causalidad entre sueño e IM y sobre la fisiopatología del sueño prolongado (≥9 h) como causante de ECV.
Mathematical modeling with constraints and research of the optimal configuration of an optical stereo system consisting of two flat mirrors and videocamera
Authors: Тищенко Игорь Петрович , Степанов Дмитрий Николаевич
Published: November 2024

Статья продолжает серию исследований, посвященных математическому
моделированию и оптимизации конфигурации оптической стереосистемы,
состоящей из видеокамеры и двух плоских зеркал. В предыдущей работе мы
разработали модель, которая учитывает различные ограничения
на конфигурацию подобной системы: величина стереобазы, размеры зеркал,
общие габариты оптической системы, отсутствие двойного отражения
световых лучей, недопущение ситуации, когда видеокамера отражается
в зеркалах. Выполнена постановка задачи условной оптимизации, в качестве
целевой функции выбран периметр прямоугольника, ограничивающий
оптическую систему.

В рамках данной работы мы добавили в модель набор ограничений,
которые задают конфигурацию рабочей зоны, она образована пересечением
полей зрения двух виртуальных камер. Соответствующие изменения были
внесены в программу для численного решения задачи условной оптимизации
с использованием пакета SciPy. Продемонстрированы примеры решения задачи
для различных исходных данных. Полученные результаты расширяют теорию
компьютерного зрения и могут быть использованы в создании и исследовании
систем компьютерного зрения для робототехнических комплексов и систем
неразрушающего контроля.
Uso da terapia de reposição hormonal no climatério e a associação com o câncer de mama
Authors: Santos Gabrielle Nunes Oliveira , Candido Isadora Eloy , Rocca Renan Remaeh
Published: November 2024

Objetivo: Determinar quais são os fatores de risco associados ao aparecimento de câncer de mama (CM) em mulheres que realizam terapia hormonal no climatério (TRH). Métodos: Revisão integrativa da literatura científica realizada através de busca sistemática nas bases de evidências da Literatura LILACS e PUBMED entre os anos 2018 e 2023. Foram encontrados 15 artigos para pesquisa. Resultados: O uso da TRH está associado ao aumento na incidência de CM, sendo estes riscos agravados por fatores associados à administração dos hormônios e riscos individuais. A incidência aumenta quanto maior a duração da reposição e proporcionalmente com a idade de início. A utilização de estrogênios vaginais tem o menor risco entre as opções, já o uso de estrogênio isolado via transdérmica ou oral apresentam menor incidência de CM do que o uso por mesma via das formulações combinadas de estrogênio e progesterona, principalmente progestágenos sintéticos. Assim como, o ganho de peso na pós-menopausa está mais associado ao risco de CM. Considerações finais: Todos os tipos de TH, exceto estrogênios vaginais, estão associados a mais incidência de câncer de mama, principalmente a combinação de estrogênio e progestagênio, especialmente em mulheres magras. Avaliação individual de risco-benefício é essencial antes da TRH para sintomas climatéricos.
Potencial Terapêutico das Plantas Medicinais Amazônicas no Tratamento da Malária
Authors: Azulay-Fernandes Caroline , Lopes Tamyris Regina Matos , Fernandes Rafael Monteiro , Miranda Felipe Kós , Brito Nalinny Coelho de , Silva Enzo Giovani Sousa da , Lobato Karla Alice Soriano de Mello , Grisolia Gianluca Cerqueira , Sousa Shirley Pantoja , Vieira José Luiz Fernandes
Published: November 2024

Objetivo: Explorar e sintetizar as evidências disponíveis sobre o uso de plantas medicinais amazônicas no tratamento da malária, destacando seus mecanismos de ação, desafios e limitações. Revisão Bibliográfica: A revisão revelou que plantas como Cinchona spp., Artemisia annua, Carapa guianensis, Copaifera spp. e Quassia amara possuem compostos bioativos que inibem a replicação do Plasmodium spp., modulam a resposta imunológica do hospedeiro e têm propriedades antioxidantes. Os principais desafios incluem a resistência do parasita aos tratamentos, a padronização das doses dos extratos de plantas e as interações medicamentosas. A integração do conhecimento tradicional com a pesquisa científica pode levar ao desenvolvimento de novos tratamentos antimaláricos eficazes. Considerações finais: As plantas medicinais amazônicas mostram um grande potencial para o tratamento da malária, porém, mais estudos são necessários para garantir a segurança e a eficácia desses tratamentos. As principais limitações incluem a resistência do parasita aos medicamentos e a necessidade de padronizar os extratos de plantas. Além disso, há dificuldades logísticas na coleta e conservação das plantas. Integrar o conhecimento tradicional com a pesquisa científica pode ser a chave para desenvolver novos tratamentos antimaláricos eficazes.
Tecnologia educacional digital para o cuidado em saúde
Authors: Padilha Jovíria Márcia Ferreira de Oliveira , Valente Geilsa Soraia Cavalcanti , Messias Cláudia Maria , Oliveira Fabiola Marchon de , Sant’Anna Rosana Moreira de , Camacho Alessandra Conceição Leite Funchal
Published: November 2024

Objetivo: Identificar e analisar as tecnologias educacionais digitais e suas implicações para o cuidado em saúde. Métodos: Revisão integrativa da literatura fundamentada nas cinco etapas de Whittemore e Knafl. Foram realizadas buscas em 13 bases de dados por artigos originais, publicados entre 2018 e 2023, em inglês, português e espanhol, que respondessem as questões norteadoras: “Quais tecnologias educacionais digitais estão sendo empregadas pela equipe de saúde para o ensino e capacitação de seus pares? E quais são as implicações dessas tecnologias educacionais digitais para o cuidado em saúde?”. Resultados: Foram selecionados 11 artigos para compor a revisão, cuja análise dos dados emergiu em duas categorias. Nestas foram descritos os benefícios e as barreiras associadas ao e-learning e à simulação em saúde, bem como foram apresentadas as suas implicações para o cuidado em saúde. Considerações finais: Os resultados permitem afirmar que tanto o e-learning quanto as simulações desempenham um papel vital na educação e capacitação dos profissionais de saúde. Conclui-se, portanto, que a integração das tecnologias educacionais digitais no processo educacional não apenas fortalece a formação dos profissionais de saúde, mas também promove a adoção de boas práticas nos espaços de saúde, contribuindo para uma assistência mais segura e eficaz.
Cobertura e meta vacinal da COVID-19 na região metropolitana de Belém
Authors: Viana Angra Thaynara Silva , Cardoso Fabiana Costa , Maia Luiz Artur Barbosa , Pinho Catarina Torres , Souza Thaynah Nunes de , Mendonça Thalita Luana do Nascimento , Fonseca Flávia Lethycia Baia da , Silva Natália da Silva , Raminho Samanta da Silva Costa , Pinheiro Maria da Conceição Nascimento
Published: November 2024

Objetivo: Descrever a distribuição da cobertura e meta vacinal Anti-Covid-19 nos municípios que compõem a região metropolitana de Belém-PA. Métodos: Estudo observacional, ecológico, com dados obtidos de um formulário eletrônico disponibilizado pela Secretária de Saúde do Estado do Pará (SESPA) e pela Rede de Dados Nacional de Saúde (RNDS). Resultados: Pfizer foi a vacina mais aplicada, as doses distribuídas foram bem maiores que as doses aplicadas, com isso as doses aplicadas não conseguiram alcançar a estimativa populacional de vacinados na Região Metropolitana I. Entre os municípios estudados, Ananindeua foi o que apresentou a melhor cobertura e a capital, Belém, a pior. A taxa de abandono da segunda para a terceira dose se mostrou um dado preocupante. Com o abandono populacional durante a campanha, muitas doses de vacina foram desperdiçadas, estragadas e descartadas. Conclusão: Esses resultados demonstram a necessidade de mais estudos e planejamentos para compreender a recusa da população para com a vacinação ou entender qual gestão mais adequada para melhores campanhas de vacinação com o intuito de elevar a cobertura vacinal e proporcionar qualidade de vida à população.
Allergens Causing Allergic Contact Dermatitis in Cosmetic Products: A Systematic Review
Authors: Oktaviani Trya , Widhiati Suci , Kariosentono Harijono , Irawanto Muhammad Eko , Oktavriana Triasari
Published: November 2024

Background: The increasing use of cosmetics worldwide has led to a rise in allergic reactions, particularly due to inadequate risk assessment. Identifying common allergens in cosmetic products causing dermatitis is crucial for effective prevention and management strategies.
Objectives: This systematic review aims to determine the list of allergens that most commonly cause allergic contact dermatitis in cosmetic products and to find the patch test positivity rate for cosmetic products. Methods: This systematic review, following the PRISMA guidelines, investigated patch test results on cosmetic-induced contact dermatitis from January 2013 to September 2023 on PubMed, Cochrane, and Medline databases. Inclusion criteria comprised retrospective cohort and clinical trial studies reporting patch test positivity rates and positive allergens in cosmetics, with eligibility determined through independent screening, full-text evaluation, and data extraction. Exclusion criteria comprised abstract-only publications, non-English or Indonesian languages, review articles, and studies with incomplete text.
Result: 13 studies were included out of 2,162 initially screened articles, involving 111,097 participants. The selected studies encompassed ten retrospective studies and three clinical trials conducted in various locations, including India, Brazil, North America, Korea, Sweden, and the Czech Republic. The patch test positivity rate ranged from 13% to 100%. The predominant allergens identified in cosmetics were nickel sulfate, fragrance mix I, cobalt chloride, para-phenylenediamine base, potassium dichromate, and balsam of Peru.
Conclusion: This systematic review highlights the diversity in patch test positivity rates and identifies key allergens responsible for allergic contact dermatitis in cosmetic products, emphasizing the need for comprehensive evaluation and awareness of cosmetic safety.
Sclerotic Fibroma in a Patient with Birt-Hogg-Dubé Syndrome
Authors: Sagut Pelin , Strat Nicholas , Dirk Elston
Published: November 2024

Birt-Hogg-Dubé syndrome (BHD) is a rare genetic disorder characterized by cutaneous lesions and systemic findings such as renal neoplasms, pulmonary cysts, and spontaneous pneumothoraces. Fibrofolliculomas, trichodiscomas, and acrochordons are the most common cutaneous lesions associated with BHD. Some cases with mucocutaneous lesions have also been reported. We report a sclerotic fibroma that developed over a previous thoracotomy scar of a patient with BHD.
Imposter Syndrome in Dermatology
Authors: Brennan Michael , Fotouhi Audrey , Daveluy Steven
Published: November 2024

Background: Dermatology residents may doubt their ability to become effective dermatologists. This study explores the prevalence of imposter syndrome (IS) within dermatology. Prior research in other specialties indicates that residents perceive themselves as less competent and experience higher rates of IS compared to faculty. Additionally, IS has been reported to be more common among female trainees.
Purpose: This study sought to identify imposter syndrome in the field of dermatology and at which point in their career dermatologists feel qualified. We hope that this information can inform residency training.
Methods: This cross-sectional study distributed a 12-question survey to the Association of Professors of Dermatology (APD) listserv.
Results: The survey received 264 responses. Of the respondents, 81.9% reported that they did not feel comfortable calling themselves a dermatologist until after their third year of residency. We found no significant differences in imposter syndrome based on gender or work experience in dermatology prior to residency. Current career level of respondents was a significant determinant of response. Lack of unsupervised practice prior to residency completion was the most commonly cited reason for imposter syndrome (81.2%).
Conclusions: The majority of dermatologists do not consider themselves a dermatologist until completion of residency, likely due to a lack of unsupervised practice. Providing residents with experiences to simulate unsupervised practice may reduce the prevalence of imposter syndrome.
Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Authors: Lebwohl Mark , Warren Richard B. , Imafuku Shinichi , Bagel Jerry , Armstrong April W. , Passeron Thierry , Banerjee Subhashis , Colombo Matthew J. , Scharnitz Thomas , Hoyt Kim , Thaçi Diamant , Blauvelt Andrew
Published: November 2024

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Deucravacitinib was efficacious and well-tolerated in the global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) parent trials and through 2 additional years in the POETYK long-term extension (LTE) (NCT04036435) trial in patients treated with deucravacitinib from Day 1 of PSO-1/PSO-2. Here, long-term efficacy was assessed through 4 years in patients who crossed over from placebo to deucravacitinib at Week 16 in PSO-1 or PSO-2 and entered the LTE trial.
Methods: PSO-1 and PSO-2 randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At Week 16, patients randomized to placebo crossed over to deucravacitinib. At Week 52, patients could enroll in the LTE and receive open-label deucravacitinib. Efficacy was evaluated in patients who crossed over from placebo to deucravacitinib at Week 16 of the parent trial and received continuous deucravacitinib through 4 years (Week 208; data cutoff, November 1, 2023). Outcomes included ≥75%/≥90% reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1). Efficacy is reported using modified nonresponder imputation (mNRI) in patients who reached the Week 208 assessment or discontinued before Week 208.
Results: Of 421 patients originally randomized to placebo, 348 crossed over to deucravacitinib at Week 16; 298 completed the parent trials and entered the LTE, with 291 meeting mNRI criteria. Efficacy response rates improved from Week 16 on placebo (PASI 75, 12.0% [95% CI, 8.5%-16.3%]; PASI 90, 3.4% [1.7%-6.2%]; sPGA 0/1, 10.0% [6.8%-14.0%]) through Week 52 on deucravacitinib (PASI 75, 75.2% [70.2%-80.2%]; PASI 90, 47.4% [41.6%-53.1%]; sPGA 0/1, 60.1% [54.5%-65.7%]). Response rates were maintained well through Week 208 (PASI 75, 75.6% [70.0%-81.2%]; PASI 90, 46.6% [40.4%-52.7%]; sPGA 0/1, 55.1% [48.8%-61.4%]).
Conclusion: These findings support the long-term efficacy profile of once-daily oral deucravacitinib for treatment of moderate to severe plaque psoriasis.
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial
Authors: Feldman Steven R. , Bagel Jerry , Hoffmann Matthias , Napoli Andrew , Cheng Chun-Yen , Dyme Rachel , Balagula Eugene , Zhong Yichen , Kempers Steven E. , Griffiths Christopher E. M.
Published: November 2024

Introduction: PSORIATYK SCALP (NCT05478499)—an ongoing 52-week, phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial—assesses the efficacy and safety of deucravacitinib in patients aged ≥18 years with moderate to severe scalp psoriasis (Psoriasis Scalp Severity Index ≥12, scalp-specific Physician Global Assessment ≥3, scalp surface area involvement ≥20%, and body surface area [BSA] involvement ≥3%). We assessed Week 16 patient-reported outcomes using Scalpdex, a validated, scalp-specific quality-of-life instrument, and numeric rating scales (NRSs) for scalp-specific symptoms.
Methods: Patients were randomized 1:2 to placebo or deucravacitinib 6 mg for 16 weeks, stratified by previous biologic use (yes or no) and body weight (<90 or ≥90 kg). Changes from baseline in Scalpdex total score and NRS scores for scalp-specific itch, pain, and flaking were assessed with an analysis of covariance (ANCOVA) model with treatment and randomization stratification factors as fixed effects and the baseline value as a covariate. Scalpdex total score change from baseline was further assessed in BSA subgroups (BSA 3–10%, BSA >10%), using an ANCOVA model with treatment as a fixed effect and the baseline value as a covariate. P values are nominal.
Results: Mean baseline scores (placebo: n=51; deucravacitinib: n=103) indicated severe impact on quality of life (Scalpdex total score >44.0) and moderate to severe symptoms (NRS ≥4.0). At Week 16, adjusted mean change from baseline (95% CI) in Scalpdex total score was greater in patients receiving deucravacitinib versus placebo (−22.3 [−26.1, −18.6] vs −10.5 [−15.7, −5.2]; P=0.0003). Changes from baseline (95% CI) in scalp-specific NRS measures were greater in patients receiving deucravacitinib versus placebo (itch: −3.2 [−3.7, −2.7] vs −0.7 [−1.4, 0.0]; pain: −2.1 [−2.6, −1.6] vs −0.1 [−0.8, 0.5]; flaking: −3.9 [−4.5, −3.4] vs −1.0 [−1.8, −0.2]; all P<0.0001). In each BSA subgroup, patients receiving deucravacitinib versus placebo reported greater Week 16 change from baseline in Scalpdex total score (BSA 3–10%: −19.8 [−23.9, −15.6] vs −10.5 [−16.1, −4.9]; P=0.0096; BSA >10%: −26.2 [−33.2, −19.3] vs −11.2 [−22.3, 0.0]; P=0.0263).
Conclusion: Deucravacitinib was efficacious in improving scalp-specific psoriasis symptoms and quality of life. Furthermore, scalp-related quality of life was improved in patients receiving deucravacitinib in both BSA subgroups.
Retrospective Analysis of the Impact of Screening for Psoriatic Arthritis (PsA) with the Psoriasis Epidemiology Screening Tool (PEST) in Clinical Dermatology Practice
Authors: Rasouliyan Lawrence , Ndefo Uche , Mummert Amanda , Althoff Amanda , Low Robert
Published: November 2024

Introduction: Patients with plaque psoriasis (PSO) have an increased risk of developing PsA as the disease severity progresses. While it is estimated that 30% of patients with PSO have PsA, nearly 16% of patients with PSO may have undiagnosed PsA.1,2 Implementing the PEST questionnaire for PsA screening in dermatologic practice may increase early intervention by improving rates of timely diagnosis.3 This observational study aimed to assess the proportion of patients with PSO and no previous PsA diagnosis who screened positive on the PEST and were then diagnosed with PsA by a healthcare provider in the PEST deployment period within the Advanced Dermatology and Cosmetic Surgery (ADCS) specialty dermatology network.
Procedure/Study: De-identified, real-world patient data [2018–2019 and 2021–2022] were sourced from electronic health records within the ADCS network of outpatient facilities across 14 states in the United States. Patients were included in the analysis if they received care at an ADCS facility where the PEST was deployed, had ≥1 encounter with a diagnosis code for PSO, and never had a diagnosis code for PsA before their first diagnosis code for PSO. For outcomes directly related to PEST evaluations, data from 1/1/2021–12/31/2022 (PEST deployment period) were used. For outcomes not directly related to PEST results, data from 1/1/2018–12/31/2019 (period before PEST deployment) were evaluated. Descriptive statistics, including frequencies, percentages, and 95% confidence intervals (CIs) for categorical variables, were used to characterize the patient cohorts by study period.
Results: Among ADCS facilities using the PEST during the deployment period (44% of practices in the network), the final study population included 14,308 and 21,142 patients with PSO in the period before PEST deployment and during the PEST deployment period, respectively. In the PEST deployment cohort, 1,100 (5.2%; 95% CI: 4.9–5.5) patients were screened using the PEST. In the period before PEST deployment, 327 (2.3%; 95% CI: 2.0–2.5) patients with PSO and no previous PsA diagnosis were subsequently diagnosed with PsA. During the PEST deployment period, 449 (2.1%; 95% CI: 1.9–2.3) patients with PSO and no previous PsA diagnosis received a subsequent PsA diagnosis without PEST screening. Of all patients with PSO who screened positive for PsA on the PEST (score ≥3; n=296), 10.8% (n=32; 95% CI: 7.6–15.1) subsequently received a formal PsA diagnosis during the PEST deployment period.
Conclusion: These results suggest that a meaningful proportion of patients with PsA may be underdiagnosed in the dermatology setting. Deployment of the PEST in the clinical dermatologic workflow may provide an opportunity to diagnose PsA earlier and improve patient outcomes.
Half-life-extended Monoclonal Antibody APG777 for Atopic Dermatitis: Design of the Phase 2 APEX Study
Authors: Guttman-Yassky Emma , Blauvelt Andrew , Gooderham Melinda , Kabashima Kenji , Oliveira Marilia , Xie Li , Wilson Angela , Dambkowski Carl , Nograles Kristine , Silverberg Jonathan
Published: November 2024

Introduction: Current treatments for moderate-to-severe atopic dermatitis (AD) include topical and systemic therapies. The latter includes monoclonal antibodies (mAbs) targeting the IL-13 pathway, which is implicated in AD pathophysiology. While currently available mAbs directed against the IL-13 pathway have demonstrated efficacy for AD, they require ongoing injections every 2 or 4 weeks. APG777 is a humanized, anti-IL-13 mAb that binds IL-13 and blocks downstream signaling mediated by the IL-13Rα1/IL-4Rα complex. APG777 contains amino acid modifications designed to extend plasma half-life through increased FcRn-mediated antibody recycling. Interim results from an ongoing phase 1 study in healthy participants suggest a favorable safety and PK/PD profile for APG777, and a half-life of approximately 75 days.
Methods: APEX (NCT06395948) is a 2-part, multicenter, phase 2, randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of APG777 in adults with moderate-to-severe AD. Adults (≥18 years of age) are eligible to participate if they have a diagnosis of AD for ≥1 year prior to screening and exhibit moderate-to-severe AD (EASI ≥16, IGA ≥3, BSA ≥10%) at both screening and baseline visits. Part A of the study (proof-of-concept) is evaluating the efficacy and safety of one induction dose regimen of APG777 compared with placebo over 16 weeks; this is followed by a 36-week maintenance period. Part B (dose-regimen finding) will evaluate different dose regimens of APG777 compared with placebo over 16 weeks followed by a 36-week maintenance period. Participants completing the maintenance period of Part A or B of the study will be eligible to enroll in a separate long-term extension study or enter the post-treatment follow-up period (up to 52 weeks). The primary outcome measure for the study is the percentage change from baseline to week 16 in the Eczema Area and Severity Index (EASI). The APEX study is currently enrolling.
Microwave Energy for Managing Hidradenitis Suppurativa
Authors: Bielecki Nicole , Hoover Aaron
Published: November 2024

Title: Microwave energy for managing Hidradenitis Suppurativa 
Nicole Bielecki PA-C and Aaron Hoover MD 
Front Range Dermatology, Greeley, CO 80634 
 
Introduction:  
Treating hidradenitis suppurativa (HS) is challenging due to its chronic, recurring nature and resistance to conventional therapies like antibiotics, anti-inflammatories, and surgery. Even with new biological treatments, there are challenges with injection site reactions. The associated pain, drainage, malodor, and scarring also significantly impact patients' mental well-being, underscoring the need for novel treatments. Four cases presented here suggest that microwave energy (ME) therapy can reduce pain, erythema and inflammation in HS lesions and even assist to resolve moderate and smaller lesions. Precise and brief surface-based applications of microwave energy to HS lesions from an FDA-cleared  microwave device intended for the coagulation of soft tissue were used to generate localized hyperthermic conditions in HS and pre-HS lesions. The rapid heating of the tissues led to subsequent clearance of moderate and small HS lesions. This was accompanied with a reduction in inflammation, draining and pain associated with these HS cases. While the outcomes are promising, the exact mechanism of action needs further investigation. These cases strongly support further research and demonstrate that ME holds promise as a novel, non-invasive treatment modality for the management of HS.  
Procedure:  
A total of 25 HS lesions from five patients were treated with ME energy. Five repetitive 2-second pulses of 3 to 4W of ME operating at 8GHz were applied to the full area of these lesions. Three to four treatment sessions were given ranging from 7 to 14 days apart.  Two patients received ME as a monotherapy, whereas the others began regimens of isotretinoin, adalimumab, or secukinumab at the same time as the first ME treatment. 
Results:  
These five patient cases demonstrate how ME treatments can lead to a rapid reduction in reported pain and erythema as well as clinical-assessed clearance of several early and moderate state HS lesions. Two of these patients only received ME as a monotherapy. However, based on clinical experience, even patients typically on medications will not typically show improvements within 7-14 days, suggesting that ME was having a rapid impact to manage pain and inflammation associated with HS lesions and in some cases assisting to resolve these lesions entirely.  
Conclusions:  
These cases report the first step in clinical feasibility and safety of microwave energy and shows promise as a novel modality for the management of HS. Although still in the early days of feasibility work, this non-invasive, fast, well-tolerated and simple treatment of microwave energy shows promise as a novel modality for the management of HS. 
Financial support: This work was supported by Emblation Ltd.
Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants with Moderate-to-Severe Acne: The Patient Journey
Authors: Baldwin Hilary , Harper Julie C. , Zeichner Joshua A , Draelos Zoe D , Eichenfield Lawrence F , Gold Michael , Stein Gold Linda , Kircik Leon H , Guenin Eric
Published: November 2024

Introduction: The main goal of acne treatment is to clear lesions quickly to manage and/or mitigate sequelae. Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination approved for acne. In three published clinical studies of participants with moderate to severe acne, CAB gel demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability. Herein are presented detailed efficacy and safety data from 5 clinical study patients to document their CAB treatment journey.
Methods: In two phase 3 (NCT04214652, NCT04214639), double-blind, 12-week studies, participants aged ≥9 years with moderate-to-severe acne were randomized to once-daily CAB or vehicle gel. Endpoints included percentage of participants achieving treatment success (≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin) and percent change from baseline in inflammatory/ noninflammatory lesion counts. Dosing compliance, treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were also assessed. Descriptive data from 5 selected cases who completed 12 weeks of CAB treatment are summarized.
Results: Participants (n=5) ranged from 13-32 years. At week 12, 3 achieved treatment success, 1 achieved a 2-grade reduction from severe to mild, and 1 achieved a 1-grade reduction from moderate to mild. Reductions from baseline to week 12 in inflammatory/ noninflammatory lesion counts ranged from 74.7-100%. No participants reported TEAEs/serious AEs. Some cutaneous safety/tolerability scores increased at weeks 2, 4, or 8, but generally decreased back to/below baselines levels by week 12, similar to the overall study populations. Most scores at week 12 were 0 (none) or 1 (mild), with only one participant reporting scores of 2 (moderate) for itching, burning, and stinging.
Conclusions: In the overall phase 3 clinical trials, fixed-dose, triple-combination CAB gel has demonstrated good efficacy, safety, and tolerability. All 5 cases presented here achieved substantial (>70%) acne lesion reductions, with 4/5 cases achieving treatment success or a 2-grade EGSS reduction by week 12. While patterns in cutaneous safety/tolerability were variable across cases, transient increases with CAB generally resolved to baseline values within two months of treatment. These clinical study cases reinforce the importance of patient education regarding efficacy and safety of acne treatment, including the importance of treatment adherence, managing patient expectations, and the potential for cutaneous effects, which are often transient.
Support: Ortho Dermatologics
Worldwide Clinical and Real-World Exposure to Baricitinib
Authors: Vleugels Ruth Ann , Craiglow Brittany , Mostaghimi Arash , Olsen Elise , Sontag Angelina , Denning Karen , Somani Najwa , Hordinsky Maria
Published: November 2024

Introduction: Baricitinib (BARI), an oral selective JAK inhibitor, is approved in many geographies for adults with rheumatoid arthritis or alopecia areata and for patients as young as age 2 years with atopic dermatitis or juvenile idiopathic arthritis. It is also approved in the US for hospitalized patients with COVID-19 infection. We report the worldwide clinical trial and real-world exposure to BARI across a range of diseases, ages and racial backgrounds.
Methods: Real-world patient exposure estimates were calculated based on total mg sold, average daily dose, and average length of therapy as reported to regulatory agencies through the cumulative timeframe ending Jan. 31, 2024. Clinical trial exposures were based on actual exposures from completed trials through Feb. 13, 2024, and estimates were made for ongoing blinded trials based on the enrolment/randomization schemes
Results: In the real-world setting, an estimated 1,836,600 patients have been exposed to the following BARI doses: 1 mg, ~2,000 (0.1%); 2 mg, ~524,900 (28.6%); 4 mg, ~1,309,600 (71.3%). Of these estimated exposures, ~ 57% were for COVID-19 with the remaining for all other indications combined. Across 59 clinical trials (completed and ongoing), an estimated 14,660 subjects (548 healthy volunteers and 14,112 patients) have received BARI since June 2008. Exposures from completed studies include 10,276 patients (62% female), 399 of whom were <18 yrs of age (≤1 month, N=4; 1 month - ≤2 yrs, N=24; >2 - ≤12 yrs, N=111; >12 - ≤18 yrs, N=260), 8820 were >18 to ≤65 yrs, 1027 were >65 yrs, and 30 had age unknown. An additional 467 adolescent and pediatric patients down to the age of 2 have been treated with BARI for atopic dermatitis in an ongoing clinical trial, bringing the total number of patients <18 years of age to 866 across dermatologic, rheumatologic, other autoimmunologic, and acute infectious diseases (excluding alopecia areata for which there is an ongoing pediatric trial). Clinical trial exposures by racial and ethnic background are as follows: Asian, N=2,491; Black, N=450; Caucasian, N=6,237; other, N=496; multiple, N=135; unknown, N=467.
Conclusion: There has been extensive real-world exposure to BARI across indications and populations, and BARI is a well-studied molecule in clinical trials, across varied disease states, racial populations and ages. Since average daily dose and length of therapy may vary over time, real-world exposures are only an estimate of total patients receiving BARI. Exposures in clinical trials include patients as young as less than 1 month of age up to patients over the age of 65 years. While these exposures do not indicate efficacy or safety, they provide data to establish the overall profile of the drug and can inform on its performance over time across a variety of populations.
In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging
Authors: Hinderks Davis Betty , Martin Brian , Morgan Sonia , Wingfield Angela
Published: November 2024

Cutaneous melanoma (CM) guidelines base management decisions on a patient’s American Joint Committee on Cancer (AJCC) tumor stage. However, limitations in staging accuracy suggest additional tools could improve risk-aligned patient management decisions. The 31-gene expression profile (GEP) test identifies patients with CM with low (Class 1A), intermediate (Class 1B/2A), or high (Class 2B) risk for sentinel lymph node (SLN) positivity, recurrence, metastasis, and death. In this multicenter, prospective study, we validated the 31-GEP for risk of recurrence and demonstrated the added value of 31-GEP to AJCC staging. 
Patients were included in the prospective CONNECTION study if they were tested with the 31-GEP from 2018 to the present (n=876). Survival was estimated using Kaplan-Meier analysis and 31-GEP stratification tested with the log-rank test. Cox regression was performed to identify predictors of recurrence. ANOVA was used to compare Cox models for the most accurate recurrence prediction. 
Patients with a Class 1A result had significantly higher 3-year recurrence-free survival than those with a Class 1B/2A or Class 2B result (98.5% vs. 80.8% vs. 63.0%, p<0.001). The 31-GEP had higher sensitivity (75.0% vs. 37.5%) and negative predictive value (98.6% vs. 96.9%) than AJCC staging. Multivariable analysis demonstrated that Class 1B/2A (hazard ratio, HR=3.12, p=0.037) and Class 2B (HR=5.91, p=0.002) were significant predictors of recurrence in addition to stage IB (HR=4.02, p=0.02), IIA (HR=6.06, p=0.006), IIC (HR=17.14, p<0.001), and III (HR=8.84, p<0.001). Stage IIB (HR=4.63, p=0.057) was not significant. Comparing a staging-only model to a 31-GEP+staging model showed that adding 31-GEP to staging significantly improved prediction accuracy over staging alone (ANOVA: c2=10.58, p=0.005).  
In this prospective study, the 31-GEP stratified risk of recurrence, was a significant predictor of recurrence, and added significant predictive value to AJCC staging. The 31-GEP identifies patients at high risk of recurrence who should be managed more intensely, and adding 31-GEP to staging allows better risk-aligned care decisions, which can lead to improved patient outcomes.
Suspected corneal metastasis in a case of nasopharyngeal carcinoma
Authors: Arora Charu , Das Dipankar
Published: November 2024

A 13-year-old girl child undergoing chemotherapy for the terminal stage of undifferentiated metastatic nasopharyngeal carcinoma presented to us with a complaint of poor vision in the left eye (LE). There were no complaints of pain, photophobia, or watering. On examination, there was asymmetric optic disc pallor in both eyes with a patch of corneal infiltration in the LE that was difficult to attribute to any obvious common pathology. The richly vascular posterior segment is a well-known target of ocular metastasis for several malignancies. Corneal involvement, if it occurs, is through local spread. However in this case, in the absence of any other factors to account for this corneal infiltration along with presence of adjacent corneal neovascularization, corneal metastasis is highly suspected. Unfortunately, histopathological evidence could not be collected due to the poor general health of the patient, who did not turn up for a follow-up.
Rehabilitation of patients with microtia and congenital atresia of the external auditory canal
Authors: D.N. Nazaryan , Kh.M. Diab , D.S. Kondratchikov , S.V. Yarancev
Published: November 2024

Aim. The purpose of the study was to create and introduce into medical practice an effective way of comprehensive aesthetic and functional rehabilitation of patients with microtia and external auditory canal atresia. Ten patients aged 4 to 18 with microtia and external auditory canal atresia were operated on. During the surgical intervention, a simultaneous operation was performed. This manipulation included the reconstruction of the auricle with a porous polyethylene implant using vascularized temporoparietal fascia, transplantation of free skin grafts, and the elimination of atresia via transmastoid access with tympanoplasty using the autofascia, the ossiculoplasty with a partial titanium prosthesis. Stable outcomes of forming an external auditory canal tube were obtained in most patients during the long-term follow-up. No cases of implant extrusion were registered. The use of an auricle frame made of a porous polyethylene implant covered with the vascularized temporoparietal fascia and free skin grafts completely recreates the anatomy of the auricle.

Цель исследования: создание и внедрение в практику эффективного способа комплексной эстетической и функциональной реабилитации пациентов с микротией и атрезией наружного слухового прохода (НСП). Прооперированы 10 пациентов в возрасте от 4 до 18 лет с атрезией НСП и микротией. В ходе оперативного вмешательства выполняли симультанную операцию – реконструкцию ушной раковины (УР) пористым полиэтиленовым имплантом с использованием васкуляризированной височно-теменной фасции, пересадкой свободных кожных трансплантатов и устранение атрезии трансмастоидальным доступом с тимпанопластикой аутофасцией, оссикулопластикой частичным титановым протезом. Получены стойкие результаты формирования трубки НСП в отдаленные сроки наблюдения у большинства пациентов. Случаев экструзии импланта не зарегистрировано. Использование каркаса УР из пористого полиэтиленового импланта, покрытого васкуляризированной височно-теменной фасцией и свободными кожными трансплантатами, полностью воссоздает анатомию УР.
ПРОБЛЕМЫ И ПЕРСПЕКТИВЫ РАЗВИТИЯ ИПОТЕЧНОГО КРЕДИТОВАНИЯ В РОССИИ
Authors: М.С. Барахоева
Published: November 2024

Ипотечное кредитование сегодня является одним из наиболее эффективных инструментов решения многих важных социальных, экономических и правовых проблем, существующих в нашей стране. Однако, по мнению многих экспертов, в экономической части ипотечное кредитование, наряду с большими перспективами, имеет и серьезные проблемы. Можно выделить ряд проблем современной российской кредитной системы: высокие темпы инфляции, монополизация рынка недвижимости, недоступность ипотеки для наименее обеспеченных слоев населения, разница в уровне спроса по регионам и нестабильность внешнеполитической ситуации.
ОСОБЕННОСТИ ПРИМЕНЕНИЯ МЕТОДА OKR ДЛЯ ПЛАНИРОВАНИЯ ДЕЯТЕЛЬНОСТИ ОРГАНИЗАЦИЙ
Authors: Н.А. Рыхтикова , Н.Я. Головецкий
Published: November 2024

Аннотация В практике современных корпораций одним из ключевых инструментов достижения плановых показателей и результатов является применение метода Objectives and Key Results (OKR) – «цели и ключевые результаты». Данный метод представляет собой совместный протокол целеполагания для компаний, команд и сотрудников с определением результатов функционирования экономических субъектов. Применение OKR позволяет получить руководству компании чёткое представление о состоянии и перспективах бизнес-процессов организации. Что, в свою очередь, позволяет повысить скорость принятия управленческих решений и результативность деятельности организации, в том числе на основе проектного подхода.
СИСТЕМА МЕТОДОВ НАУЧНЫХ ИССЛЕДОВАНИЙ, ОБЕСПЕЧИВАЮЩИХ ПОРЯДОК ЭКОНОМИЧЕСКОГО ПРОГНОЗИРОВАНИЯ В ОБЕСПЕЧЕНИИ ВОЕННЫХ РАСХОДОВ
Authors: Г.Ю. Башашкина
Published: November 2024

В статье проведен анализ метода и средств военно-научных исследований в области прогнозирования военных расходов. Научное моделирование процессов заключается в разработке математических моделей и прогнозов и оценке результатов полученных с помощью параметрических моделей процессов, для будущих периодов времени, при помощи которых приобретаются новые знания в науке как на эмпирическом, так и на теоретическом уровнях познания.
Статистический анализ занятости населения Республики Тыва
Authors: А.Ш Будегечи , Ш.Ч Соян
Published: November 2024

В статье проведено статистический анализ динамики численности занятого населения и уровень безработных в Республике Тыва и проведен прогноз до 2025 года с методом экстраполяции. Посредством использования общенаучных и экономико-статистических методов исследования проводится анализ состояния уровня занятости и безработицы Республики Тыва и рассматриваются проблемы занятости и даны пути их решения, способствующие повышению занятости населения и борьбе с безработицей в Республике Тыва. Исследование проводилось по статистическим данным за 2010–2020 гг.
СОЗДАНИЕ СИСТЕМЫ УПРАВЛЕНЧЕСКОГО АНАЛИЗА В СЕЛЬСКОХОЗЯЙСТВЕННЫХ ОРГАНИЗАЦИЯХ
Authors: О.А. Зубарева , Т.С. Игнатьева
Published: November 2024

В статье рассматриваются вопросы создания системы управленческого анализа в сельскохозяйственных организациях. Исследована трактовка понятия «управленческий анализ», выделены основные задачи, которые решаются с помощью управленческого анализа с целью принятия оптимальных управленческих решений. Наглядно представлены особенности управленческого анализа, а также содержание и организация управленческого анализа в сельскохозяйственных организациях. Исследование особенностей управленческого анализа позволило сделать вывод о том, что управленческий анализ направлен в первую очередь на выявление внутренних ресурсов и возможностей организации, на оценку текущего состояния бизнес - процессов и выявление стратегических проблем. В статье рассмотрены классические методы управленческого анализа (социальные, аналитические), широко используемые в аналитической практике сельскохозяйственных организаций. Исследована методика проведения управленческого анализа в сельскохозяйственных организациях для целей управления. Изучена информационная база управленческого анализа для сельскохозяйственных организаций. Исследована методика проведения CVP-анализа, а также приведен пример расчета прогнозного уровня безубыточности производства и запаса финансовой прочности в организации.
Ведение бухгалтерского учета на предприятиях сельского хозяйства
Authors: Д.М. Акбашева , Д.М. Абрекова , М.А. Чехова
Published: November 2024

В данной работе рассматриваются теоретические и методологические аспекты предприятия бухгалтерского учета в сельскохозяйственных компаниях. Установлены направления адаптации интернациональных стандартов финансовой отчетности. Перспективы применения МСФО 41 «Сельское хозяйство» требуют размышлений также исследований, результаты которых дадут возможность ускорить, а в последующем привести методологические принципы также правила учета биологических активов в соответствие с условиями международных стандартов финансовой отчетности.
МЕТОДИЧЕСКИЕ АСПЕКТЫ АНАЛИЗА ВАЛЮТНОГО РИСКА ПО ДАННЫМ ФИНАНСОВОЙ ОТЧЕТНОСТИ
Authors: Н.В. Котельникова
Published: November 2024

В статье предложен чек-лист анализа валютного риска на основе данных финансовой отчётности в формате МСФО. Рассмотрено в каких именно разделах финансовой отчётности стейкхолдер может найти информацию о курсовых разницах и валютных рисках. Рассмотрены примеры расчёта курсовых разниц, возникающие в результате: осуществления внешнеторговых операций на условиях отсрочки платежа; переоценки финансовых активов и обязательств, выраженных в иностранной валюте; начисления процентов по валютным кредитам. Рассмотрен пример расчёта курсовых разниц, связанных с эффектом пересчёта функциональной валюты в валюту представления отчётности. Дана краткая характеристика трансляционному, транзакционному, экономическому валютным рискам, риску пересчёта монетарных финансовых инструментов. Представлена характеристика влияния валютных рисков на разделы финансовой отчётности бизнеса.
ПРИОРИТЕТЫ ПЕРСПЕКТИВНОГО РАЗВИТИЯ И УПРАВЛЕНИЯ ИННОВАЦИОННОЙ ИНФРАСТРУКТУРОЙ НА ФОНЕ ПАНДЕМИИ COVID-19
Authors: Н.И. Лаврикова
Published: November 2024

Международное технологическое, финансовое сотрудничество и координация политических сил необходимы для подготовки развивающихся стран как для борьбы с последствиями пандемии COVID-19, так и для развития собственной цифровой инфраструктуры, с целью системного восстановления экономики в постпандемический период. В противном случае, мировая экономика к 2030 году не достигнет планируемых показателей устойчивого развития. Пандемия короновируса SARS-CoV-2 оказала значительное негативное влияние на глобальную торговлю и прямые иностранные инвестиции. По данным Всемирной торговой организации (ВТО) и Конференции ООН по торговле и развитию (ЮНКТАД) мировая торговля может сократиться на 30%, а глобальные прямые иностранные инвестиции (ПИИ) – на 30-40%. В начале марта 2020 года, когда последствия пандемии еще не затронули мировую экономику в целом, ЮНКТАД сообщил, что коронавирус уже стоил глобальной цепочке создания стоимости 50 миллиардов долларов.
ОЦЕНКА ЭФФЕКТИВНОСТИ СИСТЕМЫ ВНУТРЕННЕГО КОНТРОЛЯ УЧРЕЖДЕНИЙ БЮДЖЕТНОЙ СФЕРЫ
Authors: Т.В. Савицкая , И.А. Варпаева
Published: November 2024

Рассмотрена взаимосвязь внутреннего финансового аудита (ВФА), внутреннего финансового контроля и системы внутреннего контроля (CВК) и поставленных перед ними задач в современных условиях хозяйствования учреждений бюджетной сферы. Представлен состав и содержание федеральных  стандартов ВФА, введенных в действие с 2020 года. Изучено структурирование компонентов СВК, принятое в международной и российской практике аудита и внутреннего контроля. Определены различия в целях  и задачах оценки эффективности CВК при внешнем и внутреннем аудите деятельности учреждений. Рассмотрен метод тестирования элементов внутреннего контроля и формируемые при его использовании показатели эффективности компонентов CВК.
ОСОБЕННОСТИ НАЛОГООБЛОЖЕНИЯ СОЦИАЛЬНЫХ ПРЕДПРИЯТИЙ В РОССИИ
Authors: В.В. Тадтаева , Б.Б. Токаева , А.Б. Токаева
Published: November 2024

В данной статье раскрываются понятие и назначение, основные критерии функционирования социального предпринимательства, которое в современных условиях рассматривается как одно из средств решения накопившихся социальных проблем, а также льготное налогообложение социальных направлений деятельности предприятий, применяющих упрощенную систему налогообложения. Социальным предприятиям в соответствии с законодательством предлагается ряд систем налогообложения и налоговых льгот, направленных на оптимизацию и минимизацию налогообложения данных категорий налогоплательщиков в целях государственной поддержки их деятельности. В статье проведен анализ действующих специальных налоговых режимов для субъектов малого бизнеса, выявлены преимущества и ограничения каждого из них.